{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"InflaRx N.V."},"Symbol":{"label":"Symbol","value":"IFRX"},"Address":{"label":"Address","value":"WINZERLAER STRASSE 2, JENA, 7745, Germany"},"Phone":{"label":"Phone","value":"+49 3641508180"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings."},"CompanyUrl":{"label":"Company Url","value":"https://www.inflarx.de"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bruce P. Burnett","title":"Vice President & Head-Medical Affairs"},{"name":"Camilla Chong","title":"Chief Medical Officer"},{"name":"Daniel Vetter","title":"Senior Director & Head-IT"},{"name":"Maria Habel","title":"VP, Head-Pre-Clinical Research & Development"},{"name":"Niels Christoph Riedemann","title":"Chief Executive Officer & Executive Director"},{"name":"Renfeng Guo","title":"Executive Director & Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}